166 related articles for article (PubMed ID: 35117606)
1. High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis.
Liang M; Yu F; Wu W; Chen H; Zheng B; Zheng W; Zhu Y; Chen C
Transl Cancer Res; 2020 Apr; 9(4):2472-2481. PubMed ID: 35117606
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ
J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis.
Cui H; Li Y; Li S; Liu G
Front Oncol; 2021; 11():693886. PubMed ID: 34490091
[TBL] [Abstract][Full Text] [Related]
7. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Liu Z; Sun L; Cai L; Guo M; Xu G; Liu S; Zheng G; Wang Q; Lian X; Feng F; Zhang H
Postgrad Med J; 2022 Dec; 98(1166):948-957. PubMed ID: 34253568
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
12. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
[TBL] [Abstract][Full Text] [Related]
13. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H
Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935
[TBL] [Abstract][Full Text] [Related]
14. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy.
Jiang C; Zhu Y; Tang S; Zhang G; Lin Q; Xu Y; Shang J
Oncol Lett; 2019 Feb; 17(2):1626-1634. PubMed ID: 30675222
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Wang Q; Feng F; Wang F; Liu Z; Liu S; Xu G; Zheng G; Guo M; Lian X; Zhang H
J Cancer; 2018; 9(12):2224-2231. PubMed ID: 29937943
[No Abstract] [Full Text] [Related]
16. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
[TBL] [Abstract][Full Text] [Related]
17. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma.
Hsieh CC; Hsu HS; Li AF; Chen YJ
J Thorac Dis; 2018 Jul; 10(7):4433-4444. PubMed ID: 30174892
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Ito S; Okano S; Morita M; Saeki H; Tsutsumi S; Tsukihara H; Nakashima Y; Ando K; Imamura Y; Ohgaki K; Oki E; Kitao H; Mimori K; Maehara Y
Ann Surg Oncol; 2016 Aug; 23(Suppl 4):508-515. PubMed ID: 27380638
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
